John Lepore is SVP for R&D Pipeline at GlaxoSmithKline, where his group is responsible for R&D activities across neuroscience, rare diseases, respiratory, and metabolic and cardiovascular disease. His group is also responsible for novel models of drug discovery based on partnerships with academia as well as for ensuring excellence in GSK’s early drug discovery capabilities across the portfolio. John received his medical degree from Harvard Medical School and trained in internal medicine and cardiology at Massachusetts General Hospital. Following post-doctoral training at the Harvard School of Public Health, John joined the faculty of the Cardiovascular Medicine Division at the University of Pennsylvania where his lab studied transcriptional regulation of cardiovascular development, and he was attending physician on the academic cardiology service. John joined GSK in 2006 and had a number of roles including head of clinical pharmacology and translational medicine for cardiovascular R&D, head of the Heart Failure Discovery Performance Unit, and head of the Metabolic Pathways and Cardiovascular Therapeutic Area Unit. He is a member of key GSK R&D governance boards including the Scientific Review Board and Portfolio Investment Board, and he chairs the Discovery Investment Board and co-chairs the Technology Investment Board. John lives in the Philadelphia area with his wife and two daughters.